Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024
Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024
SANTA CLARA, Calif., April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.
加利福尼亚州圣克拉拉，2024年4月23日 /PRNewswire/ — 开发、制造和销售有助于评估和治疗慢性病的创新医疗产品和服务的公司塞姆勒科学公司（纳斯达克股票代码：SMLR）今天宣布，将在2024年5月7日星期二美国金融市场收盘后公布截至2024年3月31日的第一季度财务业绩。塞姆勒科学首席执行官道格·墨菲-丘托里安医学博士将于美国东部时间当天下午 4:30 主持电话会议。首席财务官雷娜·科米尔和首席运营官詹妮弗·奥利瓦-赫灵顿将与他一起参加电话会议。
We encourage participants to pre-register for the conference call using the following link: . Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
我们鼓励参与者使用以下链接预注册电话会议：。 预注册的呼叫者将获得会议密码和唯一的PIN，以便立即访问通话并绕过现场接线员。参与者可以随时进行预注册，包括在通话开始之前和之后。
Those without internet access or unable to pre-register may dial in by calling:
Domestic callers: 833-816-1161
International callers: 412-317-0717
那些无法上网或无法预注册的人可以通过拨打以下电话进行拨号：
国内来电者：833-816-1161
国际来电者：412-317-0717
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at .
请向操作员说明您想参加 “Semler 科学电话会议”。电话会议将存档在 Semler Scientific 的网站上，网址为。
About Semler Scientific, Inc.:
Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific has a minority investment in Mellitus, SYNAPS Dx, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool offers a technological solution for inpatient glycemic management. Additional information about Semler Scientific can be found at .
关于塞姆勒科学公司：
Semler Scientific, Inc. 开发、制造和销售有助于评估和治疗慢性病的创新产品和服务。其旗舰产品QuantaFlo已获得美国食品药品监督管理局（FDA）的专利和批准，是一种测量四肢动脉血流的快速即时检测。QuantaFlo测试有助于诊断心血管疾病，例如外周动脉疾病（PAD），塞姆勒科学正在寻求新的510（k）许可证，以扩大适应症。医疗保健提供者使用QuantaFlo来评估患者的死亡风险和重大心血管不良事件（MACE）。塞姆勒科学对Mellitus、SYNAPS Dx以及Monarch Medical Technologies LLC进行了少数股权投资，后者是一家私营公司，其产品EndoTool为住院患者血糖管理提供技术解决方案。有关 Semler Scientific 的更多信息，请访问。
CONTACT:
联系人：
Renae Cormier, CFO
[email protected]
首席财务官 Renae Cormier
[电子邮件保护]
SOURCE Semler Scientific, Inc.
来源 Semler Scientific, Inc.